12 · What may be underestimated

What may be underestimated

Erasca says 44% of 25 responded; it’s Phase 1 · No. 052 · · About 1 min read

Bookmarks need a Mind Club sign-in. How sign-in works

What may be underestimated across your briefs

Hitting normal RAS too. Daraxonrasib blocks unmutated RAS as well as mutant forms, per its label, and Erasca says ERAS-0015 is designed to do the same. That may widen the patients who respond, but it may also raise toxicity in longer first-line use; Erasca’s grade 5 pneumonitis is one case, and the combination data give no grade 3 or higher rates. Analysis